Crisci Elisa, Bárcena Juan, Montoya María
Centre de Recerca en Sanitat Animal (CReSA), UAB-IRTA, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain.
Centro de Investigación en Sanidad Animal (CISA-INIA), Madrid, Spain.
Inmunologia. 2013 Jul-Sep;32(3):102-116. doi: 10.1016/j.inmuno.2012.08.002. Epub 2012 Oct 26.
Vaccination is considered one of the most effective ways to control pathogens and prevent diseases in humans as well as in the veterinary field. Traditional vaccines against animal viral diseases are based on inactivated or attenuated viruses, but new subunit vaccines are gaining attention from researchers in animal vaccinology. Among these, virus-like particles (VLPs) represent one of the most appealing approaches opening up interesting frontiers in animal vaccines. VLPs are robust protein scaffolds exhibiting well-defined geometry and uniformity that mimic the overall structure of the native virions but lack the viral genome. They are often antigenically indistinguishable from the virus from which they were derived and present important advantages in terms of safety. VLPs can stimulate strong humoral and cellular immune responses and have been shown to exhibit self-adjuvanting abilities. In addition to their suitability as a vaccine for the homologous virus from which they are derived, VLPs can also be used as vectors for the multimeric presentation of foreign antigens. VLPs have therefore shown dramatic effectiveness as candidate vaccines; nevertheless, only one veterinary VLP-base vaccine is licensed. Here, we review and examine in detail the current status of VLPs as a vaccine strategy in the veterinary field, and discuss the potential advantages and challenges of this technology.
疫苗接种被认为是控制病原体以及预防人类和兽医领域疾病的最有效方法之一。针对动物病毒性疾病的传统疫苗基于灭活或减毒病毒,但新型亚单位疫苗正受到动物疫苗学研究人员的关注。其中,病毒样颗粒(VLP)是最具吸引力的方法之一,为动物疫苗开辟了有趣的前沿领域。VLP是坚固的蛋白质支架,具有明确的几何形状和均匀性,模仿天然病毒粒子的整体结构,但缺乏病毒基因组。它们在抗原性上通常与产生它们的病毒无法区分,并且在安全性方面具有重要优势。VLP可以刺激强烈的体液免疫和细胞免疫反应,并已显示出具有自我佐剂能力。除了适合作为其来源的同源病毒的疫苗外,VLP还可以用作多聚体呈现外源抗原的载体。因此,VLP作为候选疫苗已显示出显著的有效性;然而,只有一种基于VLP的兽用疫苗获得了许可。在这里,我们详细回顾和审视了VLP作为兽医领域疫苗策略的现状,并讨论了该技术的潜在优势和挑战。